Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07681245

Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.

This study aims to evaluate whether femtosecond laser imaging combined with FastLung AI model can provide intraoperative diagnostic performance that is non-inferior to standard frozen section diagnosis for pulmonary nodules or suspected pulmonary tumor lesions. Patients scheduled for lung surgery and requiring intraoperative pathological assessment will be prospectively enrolled. After tumor excision, the fresh tumor specimen will be bisected through the central plane. One half will be used for standard frozen section diagnosis, and the mirrored counterpart will be used for femtosecond laser imaging. Both diagnostic results will be compared with the final paraffin-embedded pathological diagnosis as the reference standard. The results of femtosecond laser imaging will not guide intraoperative clinical decision-making.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dongfang Hospital, Shanghai, Shanghai Municipality, China

Loading trial locations.

About this study

This is a prospective, multicenter, paired diagnostic accuracy study designed to evaluate the non-inferiority of femtosecond laser imaging compared with standard frozen section diagnosis for intraoperative assessment of pulmonary nodules or suspected pulmonary tumor lesions.

Eligible patients with pulmonary nodules, pulmonary space-occupying lesions, or suspected pulmonary tumor lesions who are scheduled to undergo surgical resection and require intraoperative pathological assessment will be prospectively enrolled from participating centers. After surgical excision of the tumor specimen, the fresh specimen will be bisected through the central plane. One half of the specimen will be submitted for routine frozen section diagnosis, while the mirrored counterpart will be used for femtosecond laser imaging. This paired design is intended to allow spatially corresponding comparison between the two diagnostic methods while preserving routine clinical workflow.

Frozen section diagnosis will be performed according to standard intraoperative pathological procedures and will continue to guide intraoperative clinical decision-making. Femtosecond laser imaging will be performed on fresh tissue specimens for research purposes. The imaging results will be recorded for diagnostic performance evaluation but will not be used to guide intraoperative surgical decisions.

The diagnostic results of femtosecond laser imaging and frozen section diagnosis will both be compared with the final paraffin-embedded pathological diagnosis, which will serve as the reference standard. The primary objective is to determine whether the diagnostic accuracy of femtosecond laser imaging is non-inferior to that of frozen section diagnosis. Secondary objectives may include comparisons of sensitivity, specificity, positive predictive value, negative predictive value, diagnostic concordance, and intraoperative assessment time between the two methods.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preoperative imaging suggests a pulmonary nodule, pulmonary space-occupying lesion, or suspected pulmonary tumor lesion.
  • The participant is scheduled to undergo pulmonary wedge resection, segmentectomy, lobectomy, or other pulmonary surgery.
  • Fresh lung tissue specimens can be obtained intraoperatively for femtosecond laser imaging.
  • Intraoperative frozen section diagnosis is planned to assess the nature of the tumor lesion.
  • Corresponding postoperative paraffin-embedded pathological diagnosis can be obtained.
  • The participant or the participant's legally authorized representative has signed the written informed consent form.

Exclusion criteria

  • The intraoperative specimen is insufficient and cannot simultaneously meet the requirements for routine clinical pathological diagnosis and research-related testing.
  • The specimen shows severe carbonization, necrosis, compression, contamination, or improper preservation, and the investigator determines that effective imaging cannot be completed.
  • The femtosecond laser imaging specimen cannot be matched with the corresponding lesion assessed by final paraffin pathology.
  • Final paraffin-embedded pathological diagnosis cannot be obtained.
  • The participant withdraws informed consent.
  • Other conditions that, in the opinion of the investigator, make the participant unsuitable for this study.

Treatment and study plan

Femtosecond Laser Imaging

Diagnostic Test

Fresh surgical specimens will be examined intraoperatively using femtosecond laser imaging. The imaging results will be recorded for diagnostic performance evaluation and compared with final paraffin pathology. The results will not guide intraoperative clinical decision-making.

Frozen Section Diagnosis

Diagnostic Test

Fresh tumor specimens will be evaluated intraoperatively by standard frozen section pathology. After the tumor is bisected through the central plane, one half of the specimen will be submitted for frozen section diagnosis, while the mirrored counterpart will be used for femtosecond laser imaging. Frozen section diagnosis will be used for routine intraoperative clinical decision-making and will also be compared with final paraffin pathology.

Primary outcomes

  1. Non-inferiority performance threshold

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    To determine whether FLI combined with Fast Lung achieves the prespecified non-inferiority performance threshold for benign-malignant diagnosis of the patient-level primary target lesion, using final FFPE histopathology as the reference standard.

Secondary outcomes

  1. Workflow turnaround time

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    To compare workflow turnaround time for FLI + Fast Lung and routine frozen-section pathology.

  2. Accuracy for invasive versus non-invasive/minimally invasive adenocarcinoma-spectrum lesions.

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    To evaluate the accuracy of Fast Lung for invasive versus non-invasive/minimally invasive adenocarcinoma-spectrum lesions.

  3. Sensitivity

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    To estimate the sensitivity of Fast Lung for malignant lesions using FFPE histopathology as the reference standard.

  4. Specificity

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    To estimate the specificity of Fast Lung for benign lesions using FFPE histopathology as the reference standard.

Other outcomes

  1. Diagnostic accuracy (ROC-AUC)

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    The area under the receiver operating characteristic curve (ROC-AUC) will be used to assess the overall diagnostic accuracy of FLI-FastLung model in etermination of the benign or malignant of surgical specimens compared with final paraffin pathology as the reference standard.

  2. Performance of histological subtype diagnostic

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    The performance of the FLI-FastLung model in distinguishing LUAD from LUSC will be evaluated using final paraffin pathology as the reference standard. Diagnostic performance will be quantified by area under the ROC curve (ROC-AUC), overall accuracy, sensitivity, and specificity.

  3. Performance in biopsy or small-tissue specimens

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    The performance of the FLI-FastLung model in biopsy or small tissue specimens will be assessed using final paraffin pathology as the reference standard. Diagnostic performance will be quantified by area under the ROC curve (ROC-AUC), overall accuracy, sensitivity, and specificity.

  4. Diagnostic Failure Rate

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    Diagnostic failure rate refers to the proportion of cases in which the FLI-FastLung system is unable to generate a valid histological classification result. A diagnostic failure is defined as the absence of a final output due to inadequate image quality, insufficient tissue input, or system processing failure.

  5. False Positive Rate

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    False positive rate will be calculated as the proportion of cases incorrectly classified as positive by the FLI-FastLung model when compared with final paraffin pathology as the reference standard. The result will be derived from a confusion matrix and expressed as a percentage (%).

  6. False Negative Rate

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    False negative rate will be calculated as the proportion of cases incorrectly classified as negative by the FLI-FastLung model when compared with final paraffin pathology as the reference standard. The result will be derived from a confusion matrix and expressed as a percentage (%).

  7. Heatmap-pathology concordance

    Time frame: From intraoperative diagnosis to final paraffin pathology confirmation, up to 30 days after surgery.

    Concordance between FastLung-generated heatmaps and corresponding pathological tumor regions will be evaluated using spatial overlap metrics. The primary measurement will be the Dice similarity coefficient (DSC) between model-generated heatmap regions and manually annotated pathological tumor areas. Results will be expressed as a continuous score ranging from 0 to 1.

Study contacts

Contact information is provided by the study sponsor or research team.

Xinghua Cheng, Dr. PhD.

CONTACT

[email protected]

17701681215

Sponsors and collaborators

Lead sponsor

Shanghai Chest Hospital

Other

Collaborators

  • Femtosecond Applications and Research (Guangzhou)

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 2, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.